Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 68001-541

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 68001-541). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-1 (Bortezomib Fig 1)

A Kaplan-Meier survival curve graph depicting the percentage of patients over time in months. Two lines compare patient groups labeled B-MP and MP, with B-MP showing a higher percentage of patients over time. The graph includes a p-value of 0.000002 and a table below indicating the number of patients at risk at multiple timepoints for each group.*

FDA Label Image

Fig-2 (Bortezomib Fig 2)

A Kaplan-Meier survival curve comparing the percentage of patients over time (months) between two groups labeled B-MP and MP. The chart includes the number of patients at risk at various time points below the x-axis and notes a p-value less than 0.05 from a log-rank test assessing statistical significance.*

FDA Label Image

Bortezomib-fig-5 (Bortezomib Fig 5)

A survival curve graph showing the percentage of patients over time in months, comparing two treatment groups labeled BR-CAP and R-CHOP. The vertical axis represents the percentage of patients from 0 to 100, and the horizontal axis shows time in months from 0 to 66. The graph includes a log rank test with a p-value less than 0.001, indicating statistical significance. Below the graph, the number of subjects at risk is shown for both groups at various time points.*

FDA Label Image

Bortezomib-fig-6 (Bortezomib Fig 6)

A Kaplan-Meier survival curve chart showing the percentage of subjects alive over time in months from randomization, comparing two treatment groups labeled BR-CAP (solid line) and R-CHOP (dashed line). The chart includes hazard ratio data (0.66 with 95% confidence interval 0.51 to 0.85) and a risk table showing the number of subjects at risk at various time points for each group.*

FDA Label Image

Fig-3 (Bortezomib Figure 3)

A Kaplan-Meier survival curve chart comparing the proportion of patients over time (days) between Bortezomib and Dexamethasone treatment groups. The chart shows declining patient proportions with Bortezomib data as a blue line and Dexamethasone as a red line, including the number of patients remaining at various timepoints and a p-value from a log-rank test.*

FDA Label Image

Fig-4 (Bortezomib Figure 4)

A survival curve line chart comparing the proportion of patients over time (days) between Bortezomib and Dexamethasone treatments. The graph shows patient counts at various time points and indicates a statistical significance with a p-value less than 0.05 from a log-rank test.*

FDA Label Image

Structure (Bortezomib Structure)

Chemical structure of Bortezomib, showing its molecular framework including pyridine and boronic acid groups, consistent with its identity as the active ingredient in the drug Bortezomib.*

FDA Label Image

Bortezomib Carton (Image 01)

Packaging label for Bortezomib for Injection 3.5 mg/Vial lyophilized powder for solution, intended for intravenous or subcutaneous use. The product is a single-dose vial manufactured by MSN Laboratories Private Limited for BluePoint Laboratories. The label includes storage, reconstitution, dosage instructions, and cautions about the cytotoxic nature of the agent, along with barcodes and coding information.*

FDA Label Image

Bortezomib Label (Image 02)

Bortezomib for Injection 3.5 mg/vial label from BluePoint Laboratories. The lyophilized powder vial contains 3.5 mg bortezomib, intended for intravenous or subcutaneous use. The label includes storage instructions, a caution that it is a cytotoxic agent, the NDC 68001-541-36, and manufacturing details from MSN Laboratories Private Limited, India.*

FDA Label Image

Bortezimib Intravenous Sticker (Image 03)

Label for Bortezomib for Injection showing instructions for intravenous injection only. The label indicates adding 3.5 mL of 0.9% Sodium Chloride to achieve a final concentration of 1 mg/mL. It includes placeholders for stickers on the vial and syringe labeled Intravenous Bortezomib. Additional reference to package insert Section 2 for full instructions is provided.*

FDA Label Image

Bortezomib Subcutaneous Sticker (Image 04)

Label for Bortezomib injection for subcutaneous use only, showing preparation instructions to add 1.4 mL of 0.9% sodium chloride to achieve a final concentration of 2.5 mg/mL. The label includes directions to place stickers on vial and syringe and references the package insert for full instructions. The label mentions a revision date of 05/22.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.